The area densities of DLL4-positive tumor vessels were 0.40 ± 0.03% in vehicle, 0.24 ± 0.03% in irinotecan, 0.11 ± 0.02% in mABL001, and 0.05 ± 0.01% in the combination treatment group, respectively (Figure 4B). This evidence concerns the gene DLL4 and neoplasm.